Ardy Arianpour is CEO & Co-Founder of Seqster, the leading patient-centric SaaS healthcare technology company that enables organizations to drive efficient healthcare via comprehensive medical records (EHR), individual genomic profiles (DNA), and personal health device data. For the first time, users create their own matched, longitudinal health data profile across all of their US-based healthcare data sources through patient-centric interoperability.
Ardy is a visionary health tech executive and serial entrepreneur in biotech and digital health. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics, and served as SVP of Ambry Genetics, which sold to Konica in 2017 for $1 Billion.
As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country.
Ardy received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management. He was a Medical, Marketing, and Media’s (MM&M) Top 40 Healthcare Transformer and San Diego Business Journal 40 under 40.
Steve Bourke is a dynamic patient advocate representing EUPATI CH (The European Patients’ Academy, Switzerland), the experts in patient engagement for the DayOne Hackathon. He is the founder of PersonalPulse GmbH, empowering people who are patients, and a co-founder of RheumaCura Foundation; rheumatic and musculoskeletal diseases can be prevented and cured. He is also co-moderator of the patient advisory board for the PharmaLedger Project. His passion is to remove the stigma around disease through clear and effective health communications while empowering people with elegant technological solutions to manage the daily burden of disease. He is ideally positioned with a background in exercise physiology, biomedical research and health communications to “Empower people who are patients.”
Christina Busmalis is Director at Google Cloud responsible for the Life Science Industry leader in EMEA. Previously she was at IBM Watson Health as the Global Life Sciences go-to-market leader Europe & Asia Pac. Prior to this role Christina was the global director of technology for the IBM account team, working with Novartis for 12 years where she focused on identifying and leveraging disruptive technologies to address complex business challenges across the life sciences value chain. She has over 26 years of executive leadership, consulting, business development and project management expertise across Europe, US, and Asian markets and is based in Zurich, Switzerland.
Ventsislav Dobrev is Commercial Execution Manager Central and Eastern Europe at Novartis. Working for more than 11 years in Novartis in different areas such as Clinical Operations, Medical affairs, Marketing and sales and Business excellence. Ventsi is currently focused on the digital and business transformation in Pharma, which was accelerated by COVID.
Blaise Jacholkowski, EPFL Eng, MBA, Principal Business Consultant at Zühlke, spent most of his career in strategic consulting and professional services within the life science space, notably working with Pharmaceutical and Medtech companies. During the past few years, he has been an active entrepreneur in the health tech area, most recently in the field of symptoms management for cancer patients. He has been invited at some conferences to speak about entrepreneurship in the health space and provide webinars on topics such as Digital Therapeutics and Patient Engagement. He joined Zühlke at the end of 2020, at a time where digital technologies are increasingly changing the way healthcare is delivered and where new ecosystems are being created.
Professor Ilona Kickbusch (@IlonaKickbusch) is the Founder of the Global Health Centre at the Graduate Institute in Geneva. Her areas of expertise include the political determinants of health, health in all policies, and global health. She advises countries on their global health strategies, trains health specialists, and is involved in German G7 and G20 health activities. She publishes widely and serves on various commissions and boards. Ilona is a member of the Global Preparedness Monitoring Board and Co-Chair of UHC 2030, and the Lancet and Financial Times Commission title Governing health futures 2030: Growing up in a digital world. She has had a distinguished career with the WHO. She was a key instigator of the Ottawa Charter for Health Promotion and WHO’s Healthy Cities Network and has remained a leader in this field, most recently advising on WHO’s activities related to Health in the SDGs. She was the Director of the Global Health Division at Yale University School of Public Health and responsible for the first major Fulbright Programme on global health.
Renata is primary care pediatrician by training. She completed the residence in pediatrics in her native Slovakia, followed by training in public health in applied sciences in Switzerland. She has 20+ years’ working and leadership experience in clinical drug development, regulatory affairs, learning & development, and patient engagement across CRO and major global pharmaceutical companies. Prior to Noema, Renata has worked at Hoffmann-La Roche where she led initiatives with a focus on patient engagement, including developing real world data concept to identify the most impactful approaches to engage with patients.
In her current role as Vice President Development, Pediatric Programs at Noema Pharma she leads a development of a rare disease treatment. Since she joined last year, she also spearheaded a number of successful initiatives and positioned Noema as a true partner in patients’ journey.
Renata is based in Basel and is an avid supporter of Basel Area Swiss, the most memorable experience being the Day One Health Hack in 2020 where she was the patient champion on the winning Hawking’s Mate team
Thomas Müller is an Associate Partner in McKinsey’s Zurich office. He is core of McKinsey’s Digital and Technology practice in Europe and has extensive experience in the health care and public sector. He has a passion for improving people’s health and lives leveraging the innovation opportunities from digital technologies across the various stakeholders of healthcare systems. He leads the Swiss chapter of the McKinsey healthtech network and has co-authored and contributed to several articles about digital health. He studied Applied Mathematics with a focus on Computational Mathematics and Super Computing at Albert-Ludwigs-Universität Freiburg and Pontificia Universidad Católica de Chile. He holds a Ph.D.
In her day-to-day work, Belinda works tirelessly to include the patient voice along the entire lifecycle of a medicinal product. She drives the patient-centric brand strategy for Germany and acts as a primary point of contact for the patient community. Belinda is a passionate ambassador for partnering with the patient community at eye level to create innovative solutions that bring true value to entire health ecosystems. She´s convinced that nothing for patients should be done without patients – and that only through collaboration we may change the future of health.
Prior to her current position, Belinda served the patient community in different roles. She started off as a postdoctoral researcher at the University Hospital Basel, leading several international multi-stakeholder research projects on improving the value of clinical trials by engaging patients more systematically. She then entered the pharmaceutical industry as an intern in Global Market Access at Novartis before becoming Global Patient Innovation Director at F. Hoffmann-La Roche.
Belinda holds a PhD in Clinical Research where she graduated summa cum laude from the University and University Hospital Basel, an MSc in International Health Policy & Economics from the London School of Economics, and an MSc in Biochemistry from ETH Zurich and Harvard University.
In her spare time, Belinda is a passionate cook who enjoys traveling to new places, always looking for new flavors to add to her recipe portfolio. She relaxes best by doing sports in nature. Belinda currently lives in Basel, Switzerland.
David Rowan explains compellingly how emerging technologies will impact business — and how leaders should prepare now. As founding Editor-in-Chief of WIRED magazine’s UK edition, David came to know the founders of WhatsApp, LinkedIn, Google, Didi, Spotify, Xiaomi, Nest, Twitter and countless other ambitious startups from Tel Aviv to Shenzhen. He has since invested in more than 60 early-stage tech companies, including two that became billion-dollar “unicorns”, and is an adviser to Lakestar, one of Europe’s largest venture-capital funds. His best-selling book “Non-Bullshit Innovation: Radical Ideas from the World’s Smartest Minds” (Penguin, 2019) has been published in Japan, Korea, Russia and beyond. David has been a technology columnist for The Times, GQ, Condé Nast Traveller and The Sunday Times, and hosts a podcast series about tech founders called Walks With Founders.
Thomas Schertenleib has worked in innovation projects with multiple companies in the health care ecosystem. They comprehend a variety of design scopes from the interaction design of purchasing processes of medical devices and health insurance products to the UX of digital and blended learning services in the context of ethics in medicine to more Service Design oriented work with a focus on rare diseases.
For Thomas, good design is more than engaging digital experiences. His goal is to design experiences that play a meaningful role in patients, care-givers and HCP’s lives.
Robert Scott is Head of Product & Portfolio Network at the Novartis Biome. The Novartis Biome unites the best of science and technology together with ecosystem partners to create impactful healthcare solutions and patient experiences, at scale. Previous to Novartis, Rob led Digital, Innovation & Experience Strategy for a number of Life Science clients at Accenture, and led Digital Transformation and Innovation programs at Takeda and Syngenta. Previous to Life Sciences, Rob worked in Technology and Media.
Angela is a Senior Partner and Industry Lead, EMEA Healthcare & Life Sciences for IBM Global Business Services.
She has spent over two decades working with health systems, public and private hospitals, insurers and digital innovators on value-based care, digital health and advanced analytics.
Angela was formerly a Partner with McKinsey & Company’s Health Systems and Services Practice in London and leader of the McKinsey Center for Health Improvement in Europe. In her global role, Angela led McKinsey’s Advanced Analytics team for patients with chronic conditions, advising leading US health insurers, Medicaid programmes and private hospitals. She also held geographic leadership roles as head of Healthcare for LATAM and Iberia.
Kaspar Sutter has been head of the Department of Economic Affairs, Social Affairs and the Environment of the Canton of Basel-Stadt since February 2021, with responsibility for the national economy, social insurance and social welfare, and environmental and energy policy. He represents the canton on the board of directors of EuroAirport and the Swiss Rhine ports, among others.
Sezai holds a MBA from the University of Basel and brings 20 years of pharmaceutical industry experience. He started his career in finance and moved to commercial roles. Sezai was a recognized business leader in hematology and oncology at Roche, Abbvie and AZ, at the regional and international level. He supervised the launch, marketing and commercialization of numerous leading franchises across multiple therapeutic areas. Among others he launched PERJETA, Kadcyla, TECENTRIQ, VECLYXTO and ENHERTU across different hematology and solid tumor indications. In his last role he helped to build up the alliance of AZ and Daiichi Sankyo in Europe. At owkin, Sezai is responsible for the strategic partnerships with pharma and biotech companies.
Casper is a physicist by education and has 18+ years of experience building large scale systems for data processing, analysis, and artificial intelligence.
Casper is a founder and the CEO of Abzu, the deeptech startup whose proprietary artificial intelligence, the QLattice, accelerates analysis and insights through transparent and explainable models. At Abzu, Casper applies his passions for advanced data analysis and adaptive/responsive systems to achieve his dream of revolutionizing artificial intelligence.
Casper enjoys speaking about the ethical impacts of using AI in decision-making and Abzu’s unique teal organization. There are no bosses at Abzu, and everyone sets their own salaries and schedules – ask him about it! Casper loves to wax profane on all things philosophical and technological.
Lucas Scherdel has been working for Basel Area Business & Innovation in 2021.
Previously, he worked in a number of digital and strategic roles in global and regional functions, including the European and global offices of the World Health Organization and the UK’s National Health Service. He also led the Global Coalition for Value in Healthcare at the World Economic Forum.
Lucas Scherdel completed his BSc in neuroscience in the UK and has a Masters degree in politics, philosophy and economics of health from University College London. In 2020, Lucas Scherdel was named on the Forbes list 30 under 30 for science and healthcare in Europe for his contributions towards healthcare.